par Fumagalli, Debora 
;Venet, David ;Ignatiadis, Michail ;Abdel Azim, Hatem Hamdy ;Maetens, Marion M. ;Rothé, Françoise ;Salgado, Roberto;Bradbury, Ian;Pusztai, Lajos;Harbeck, Nadia;Gomez, Henry;Chang, Tsai-Wang;Coccia-Portugal, Maria;Di Cosimo, Serena;de Azambuja, Evandro ;de la Peña, Lorena;Nuciforo, Paolo;Brase, Jan JC;Huober, Jens;Baselga, José;Piccart-Gebhart, Martine ;Loi, Sherene ;Sotiriou, Christos
Référence JAMA oncology, 3, 2, page (227-234)
Publication Publié, 2017-02
;Venet, David ;Ignatiadis, Michail ;Abdel Azim, Hatem Hamdy ;Maetens, Marion M. ;Rothé, Françoise ;Salgado, Roberto;Bradbury, Ian;Pusztai, Lajos;Harbeck, Nadia;Gomez, Henry;Chang, Tsai-Wang;Coccia-Portugal, Maria;Di Cosimo, Serena;de Azambuja, Evandro ;de la Peña, Lorena;Nuciforo, Paolo;Brase, Jan JC;Huober, Jens;Baselga, José;Piccart-Gebhart, Martine ;Loi, Sherene ;Sotiriou, Christos Référence JAMA oncology, 3, 2, page (227-234)
Publication Publié, 2017-02
Article révisé par les pairs
| Résumé : | In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancers with dual HER2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targeted agent alone. Amplification and/or overexpression of HER2 currently remains the only biomarker for therapeutic decisions, but it is insufficient to explain the heterogeneous response to anti-HER2 agents. |
